Abstract
Objectives: The objective of this study was to evaluate the pharmacotherapy of bipolar II disorder during pregnancy and the postpartum period.
Methods: The use of psychotropic drugs and recurrence risk during and after pregnancy was studied in a prospective, observational study of 37 women with bipolar II disorder.
Results: During pregnancy the majority of participants (54.0%) were not on any psychotropic medication, approximately one third (32%) received monotherapy, and the rest were on combination therapy. In comparison, during the postpartum period only 14% of participants were not on any psychotropic medication, approximately 35% received monotherapy, and over 50% were on combination therapy. While only 13.5% of participants were on 3 or more psychotropic drugs during pregnancy, 21.6% required 3 or more psychotropic drugs after childbirth in order to manage their symptoms. During pregnancy, 51 % of women had a mood episode compared to a recurrence rate of 70% in the postpartum period.
Limitations: Small sample size, lack of a control group, and absence of random treatment assignment.
Conclusions: The findings of this prospective, observational study indicate that the recurrence risk is much higher after childbirth than during pregnancy in spite of higher utilization of psychotropic drugs in the postpartum period.
Keywords: Bipolar disorder, childbirth, drug treatment, postpartum, pregnancy.
Current Drug Safety
Title:Pharmacotherapy of bipolar II disorder during and after pregnancy
Volume: 8 Issue: 4
Author(s): Verinder Sharma, Christina Sommerdyk, Bin Xie and Karen Campbell
Affiliation:
Keywords: Bipolar disorder, childbirth, drug treatment, postpartum, pregnancy.
Abstract: Objectives: The objective of this study was to evaluate the pharmacotherapy of bipolar II disorder during pregnancy and the postpartum period.
Methods: The use of psychotropic drugs and recurrence risk during and after pregnancy was studied in a prospective, observational study of 37 women with bipolar II disorder.
Results: During pregnancy the majority of participants (54.0%) were not on any psychotropic medication, approximately one third (32%) received monotherapy, and the rest were on combination therapy. In comparison, during the postpartum period only 14% of participants were not on any psychotropic medication, approximately 35% received monotherapy, and over 50% were on combination therapy. While only 13.5% of participants were on 3 or more psychotropic drugs during pregnancy, 21.6% required 3 or more psychotropic drugs after childbirth in order to manage their symptoms. During pregnancy, 51 % of women had a mood episode compared to a recurrence rate of 70% in the postpartum period.
Limitations: Small sample size, lack of a control group, and absence of random treatment assignment.
Conclusions: The findings of this prospective, observational study indicate that the recurrence risk is much higher after childbirth than during pregnancy in spite of higher utilization of psychotropic drugs in the postpartum period.
Export Options
About this article
Cite this article as:
Sharma Verinder, Sommerdyk Christina, Xie Bin and Campbell Karen, Pharmacotherapy of bipolar II disorder during and after pregnancy, Current Drug Safety 2013; 8 (4) . https://dx.doi.org/10.2174/15748863113089990037
DOI https://dx.doi.org/10.2174/15748863113089990037 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Translocator Protein as a Promising Target for Novel Anxiolytics
Current Topics in Medicinal Chemistry Dynamics of Diabetes and Obesity: An Alarming Situation in the Developing Countries in Asia
Mini-Reviews in Medicinal Chemistry Role of Adenosine Kinase Inhibitor in Adenosine Augmentation Therapy for Epilepsy: A Potential Novel Drug for Epilepsy
Current Drug Targets Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue:Classic and New Agents to the Treatment of Affective Disorders: Some Concerns and Perspectives
Current Psychopharmacology L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery PON1 Hypermethylation and PON3 Hypomethylation are Associated with Risk of Cerebral Infarction
Current Neurovascular Research Nitric Oxide is a Key Molecule Serving as a Bridge between Radiation-Induced Bystander and Adaptive Responses
Current Molecular Pharmacology Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19
Current Pharmaceutical Design PPAR-γ Agonists as Regulators of Microglial Activation and Brain Inflammation
Current Pharmaceutical Design Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery
Current Medicinal Chemistry Serum Amyloid Beta Peptides in Patients with Dementia and Age-Matched Non-Demented Controls as Detected by Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS)
Current Clinical Pharmacology Oxidative Stress and Heavy Metal Levels of Pholiota limonella Mushroom Collected from Different Regions
Current Chemical Biology Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) Drug Treatment of Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-picking) Disorder, and Nail-biting (Onychophagia)
Current Neuropharmacology Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Ginsenoside RB1 Reduces Neurologic Damage, is Anti-Apoptotic, and Down-Regulates p53 and BAX in Subarachnoid Hemorrhage
Current Neurovascular Research